![A hospital room with a bed, IV cart and other equipment](https://www.uc.edu/news/articles/2023/12/n21213856/jcr:content/image.img.cq5dam.thumbnail.500.500.jpg/1701708501951.jpg)
The Oncology Nursing Podcast: UC expert discusses antimetabolite drugs
The University of Cincinnati's Rowena Schwartz joined The Oncology Nursing Podcast to discuss what oncology nurses need to know about a class of chemotherapy drugs called antimetabolites.
Schwartz, PharmD, said antimetabolites are some of the oldest anti-cancer drugs that are "developed to be similar to naturally occurring compounds that are important in cell production." They work in different ways to accomplish the goal of killing cancer cells, and also have uses as antibacterial drugs, she said.
Each drug has different potential side effects, and even the same drug can have different side effects when given at different doses and regimens, Schwartz said, highlighting the need for every member of an oncology care team to be familiar with each specific drug, dose and regimen.
"If I don’t use a drug often, I will always look it up again before I do any kind of education for a patient," said Schwartz, professor of pharmacy practice at UC's James L. Winkle College of Pharmacy. "If I don’t use [a drug] routinely in my practice, I always find myself reviewing it just to make sure that a nuanced side effect that may be very important for a patient, I will go over."
Patient education is a job for the whole team, Schwartz said, and there needs to be collaboration between doctors, nurses and pharmacists.
"I think that in this day and age it is really important that there’s collaboration in developing whatever resources that we have," she said. "I guess that goes even beyond order sets to the education we deliver to patients to make sure it’s a consistent message. I think that is essential that the team knows what everybody is going to say so that it is consistent, because patients get so confused."
Even though antimetabolites are an older type of drug, Schwartz said she believes they will remain an important part of cancer treatment.
“I think that there are certain agents that are so foundational in some diseases that they will remain. Whether they remain first-line, maybe not; maybe they’ll go to second line as we see things evolve with new agents," she said. "Some of these drugs have been very effective in the diseases in which they are used to treat patients. There’s a long term place in therapy for these, and I think that we'll still be using these.”
Listen to The Oncology Nursing Podcast.
Featured photo at top of hospital room. Photo/Dmitri Karastelev/Unsplash.
Related Stories
Drug Discovery News: Silence in healthy cells makes FOXR2 a potential cancer target
April 7, 2023
Drug Discovery News highlighted research coauthored by the University of Cincinnati's Timothy Phoenix that found a gene called FOXR2 is abnormally expressed in more than 70% of cancer types sampled and could be a potential target for new treatments.
Physics World: Engineered bacteria attract cancer-killing radioisotopes into tumors
April 14, 2023
Physics World highlighted research led by the University of Cincinnati's Nalinikanth Kotagiri that shows a proof of concept for using engineered bacteria as an adapter to deliver targeted radionuclide treatment to tumors.
The Oncology Nursing Podcast: UC expert discusses antimetabolite drugs
December 4, 2023
The University of Cincinnati's Rowena Schwartz joined The Oncology Nursing Podcast to discuss what oncology nurses need to know about a class of drugs called antimetabolites.
MedPage Today: Promising results for living donor transplants
April 5, 2022
The University of Cincinnati's Shimul Shah, MD, was featured in a MedPage Today article highlighting recent research on the success of living donor transplants for patients with unresectable colorectal cancer liver metastases.
Yahoo! News: Electricity cap used to treat brain tumors
April 18, 2022
Yahoo! News featured University of Cincinnati research into the use of Optune devices that provide electrical field treatment to the brain as a treatment for glioblastomas.
WCPO: UC's Wahab works to address breast cancer disparities
November 9, 2022
WCPO featured the University of Cincinnati's Rifat Wahab in an article about racial disparities in breast cancer diagnoses and work being done to address the issue.
Media highlight UC's FLASH radiotherapy trial
October 25, 2022
National media outlets highlighted the results of the first-in-human trial of FLASH radiotherapy, led by University of Cincinnati Cancer Center researchers.
MSN: Researchers study how immunotherapy affects COVID-19 outcomes
November 7, 2022
MSN India highlighted recent research led by the University of Cincinnati's Trisha Wise-Draper about how immunotherapy and immunosuppression affects COVID-19 severity.
Healio: Immunotherapy does not increase surgery complications for oral cavity cancer patients
May 2, 2022
The University of Cincinnati's Alice Tang was featured in a Healio article discussing recently published research that administering an immunotherapy drug prior to surgery did not increase risks for patients with advanced oral cavity cancer.
Imaging Technology News: First FLASH proton therapy trial completed in humans
May 27, 2022
The University of Cincinnati's John Breneman, MD, spoke with Imaging Technology News about the completion of enrollment of the FAST-01 trial, the first FLASH proton therapy trial completed in humans.